AGNPF 0.07 Algernon Pharmaceuticals Inc.
Range: | 0.0353-0.123 | Vol Avg: | 4112 | Last Div: | 0 | Changes: | 0 |
Beta: | -0.4 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
Sector: | Healthcare | IPO: | Fri Mar 11 2016 | Empoloyees: | |
CUSIP: | 01559R400 | CIK: | 0001642178 | ISIN: | CA01559R4008 | Country: | CA |
CEO: | Mr. Christopher J. Moreau | Website: | https://algernonpharmaceuticals.com |
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.